Clinical trialObservationalUnknown
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques
- Outcome
- Outcome unknown
- Phase
- Observational
- Status
- Unknown
- Study type
- Observational
- Start
- 13 May 2021
- Listed end
- 12 March 2022
- Enrollment
- 20 participants
- Sites
- 1
- Primary outcomes
- Differentially expressed proteins in tumor and paracancer tissues
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 21 October 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.
Detailed description public domain (ClinicalTrials.gov)
This study plan from the affiliated hospital of Qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.